Medtronic, Inc.has announced the initiation of a feasibility study of an interventional treatment for erectile dysfunction that uses a specially-designed drug-eluting stent system.
Stents
Boston Scientific Completes Enrollment in International Benign Stricture Study of WallFlex® Biliary RX Stent
Boston Scientific Corporation has completed enrollment in a clinical trial to evaluate its WallFlex® Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures.
New Duodenal Stent gains FDA approval: Provides Relief to Patients with Advanced Small Intestine Cancer
Cook Medical has announced that its Evolution® Duodenal Controlled-Release Stent was recently granted 510(k) clearance by the Food & Drug Administration (FDA)
FDA in the Spotlight again as All Metal Hip Implants and Brain Stents Referenced as Examples of Harms Created by Underregulation
Republicans have been urged to hold hearings to examine certain medical devices, which have developed serious defects after being implanted in patients.
Boston Scientific Corporation announces two-year data from its SYNTAX clinical trial
Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS® EXPRESS® Stents and Bypass Surgery.
Abbott Launches Next-Generation XIENCE PRIME™ Drug Eluting Stent in International Markets
Abbott today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
Micrus Endovascular Signs Licensing and Development Agreement for Flow Diversion Technology
Micrus Endovascular Corporation and Flexible Stenting Solutions Inc. today announced the signing of an exclusive agreement to jointly develop a flow diversion technology for neurovascular indications.
FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer
FlowCardia, Inc., a worldwide leader in the development of endovascular devices for the treatment of chronic total occlusions (CTOs), today announced the appointment of Chris Barys to the position of Chief Operating Officer.
Abbott Receives CE Mark For Company’s Next-Generation XIENCE PRIME™ Drug Eluting Stent
Abbott announced that it has received CE Mark for its next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.
CorNova® Receives CE Mark Approval For Valecor Platinum® Coronary Stent System
CorNova Inc. announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System.
Abbott Initiates Trial of Next-Generation XIENCE PRIME™ Drug Eluting Stent
Abbott today announced the initiation of SPIRIT PRIME, a clinical trial to study the performance of the company’s next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
Talent Stent Graft Shows Durable Performance in Patients with Abdominal Aortic Aneurysms
Through five years following initial implantation in an FDA-approved study, the Talent Abdominal Stent Graft from Medtronic, Inc., demonstrated durable safety and effectiveness in patients with abdominal aortic aneurysms.
Endograft Introduction System Enhances Control During Thoracic Aortic Aneurysm Treatment
Physicians will now experience a new level of control while placing endografts during thoracic endovascular repair procedures, with the launch of Cook Medical’s new Z-TRAK PLUS™ Introduction System.
Olympus Broadens Portfolio With New Biliary Metallic Stent
Olympus America Inc. has expanded its medical portfolio by introducing the X-Suit NIR®, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support.
Drug-Eluting Stents More Effective Than Bare-Metal Stents In Heart Attack Patients
NewYork-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation, announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine.
FDA Approves Boston Scientific’s Next-Generation TAXUS® Liberte® Atom™ Stent System
Boston Scientific Corporation today announced it has received approval from the U.S. Food and Drug Administration to market its TAXUS® Liberte® Atom™ Paclitaxel-Eluting Coronary Stent System.